There have been reports of inadvertent overdosage with timolol ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. Very limited information exists on accidental ingestion of brimonidine in adults alone or in combination. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine ophthalmic solutions as part of medical treatment of congenital glaucoma or by accidental oral ingestion [see Use In Specific Populations]. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.

Asthma, COPD

COMBIGAN® is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS].

Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock

COMBIGAN® is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure [see WARNINGS AND PRECAUTIONS]; cardiogenic shock.

Neonates and Infants (Under the Age of 2 Years)

COMBIGAN® is contraindicated in neonates and infants (under the age of 2 years).

Hypersensitivity Reactions

Local hypersensitivity reactions have occurred following the use of different components of COMBIGAN® . COMBIGAN® is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.

Last reviewed on RxList: 10/19/2012
This monograph has been modified to include the generic and brand name in many instances.